journal article·2018-03Open access

A Vesicular Stomatitis Virus‐Inspired DNA Nanocomplex for Ovarian Cancer Therapy

Wei Zhao, Yuping Yang, Lingling Song, Tianyi Kang, Ting Du, Yujiao Wu, Meimei Xiong, Li Luo, Jianlin Long, Ke Men, Lan Zhang, Xiaoxin Chen, Meijuan Huang, Maling Gou

Advanced Science· Volume 5· Issue 3

Abstract

Abstract Gene therapy provides a novel method for cancer therapy. This study shows a DNA nanocomplex that is inspired from vesicular stomatitis virus (VSV) for ovarian cancer therapy. This DNA nanocomplex consists of a cationized monomethoxy poly (ethylene glycol)‐poly (d,l‐lactide) (MPEG‐PLA) nanoparticle and a plasmid encoding the matrix protein of vesicular stomatitis virus (VSVMP) that plays a critical role in the VSV‐induced apoptosis of cancer cells. The cationized MPEG‐PLA nanoparticle that is self‐assembled by MPEG‐PLA copolymer and N‐[1‐(2,3‐dioleoyloxy) propyl]‐N,N,N‐trimethylammonium chloride (DOTAP) has low cytotoxicity and high transfection efficiency (>80%). Intraperitoneal administration of the pVSVMP nanocomplex remarkably inhibits the intraperitoneal metastasis of ovarian cancer and does not cause significant systemic toxicity. The apoptosis induction and anti‐angiogenesis are involved in the anticancer mechanism. This work demonstrates a VSV‐inspired DNA nanocomplex that has potential application for the treatment of intraperitoneal metastasis of ovarian cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Virus-based gene therapy research · Animal Virus Infections Studies · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University, and Collaborative Innovation Center for Biotherapy Chengdu 610041 P. R. China

Department of Thoracic Oncology Cancer Center and State Key Laboratory of Biotherapy West China Hospital West China Medical School Sichuan University Chengdu 610041 P. R. China

Community Health Service Administration Center Shenzhen Longhua New District Central Hospital Shenzhen 518110 P. R. China

Research and Development Department Guangdong Zhongsheng Pharmacy Dongguan 523325 China

Funding

National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.3322/caac.2125410.3322/caac.21254 ↗
2. 10.1158/1078-0432.CCR-12-224310.1158/1078-0432.CCR-12-2243 ↗
3. 10.1016/S0140-6736(14)62223-610.1016/S0140-6736(14)62223-6 ↗
4. 10.1016/j.ygyno.2005.07.11710.1016/j.ygyno.2005.07.117 ↗
5. 10.1021/nn100559910.1021/nn1005599 ↗
6. 10.1099/vir.0.046672-010.1099/vir.0.046672-0 ↗
7. 10.1016/j.virol.2014.10.02610.1016/j.virol.2014.10.026 ↗
8. 10.1128/JVI.65.9.4950-4958.199110.1128/JVI.65.9.4950-4958.1991 ↗
9. 10.1371/journal.ppat.100271210.1371/journal.ppat.1002712 ↗
10. 10.1016/j.freeradbiomed.2011.09.03510.1016/j.freeradbiomed.2011.09.035 ↗
11. 10.1002/jgm.269810.1002/jgm.2698 ↗
12. 10.1038/sigtrans.2015.410.1038/sigtrans.2015.4 ↗
13. 10.1038/nature1581810.1038/nature15818 ↗
14. 10.1128/JVI.66.7.4058-4064.199210.1128/JVI.66.7.4058-4064.1992 ↗
15. 10.1126/science.112695310.1126/science.1126953 ↗
16. 10.1128/JVI.64.4.1716-1725.199010.1128/JVI.64.4.1716-1725.1990 ↗
17. 10.1128/JVI.79.7.4170-4179.200510.1128/JVI.79.7.4170-4179.2005 ↗
18. 10.1128/MMBR.00007-1110.1128/MMBR.00007-11 ↗
19. 10.1038/nrg376310.1038/nrg3763 ↗
20. 10.1016/j.addr.2017.07.02110.1016/j.addr.2017.07.021 ↗
21. 10.1002/adma.20160309510.1002/adma.201603095 ↗
22. 10.2217/nnm.12.14510.2217/nnm.12.145 ↗
23. Eiselein J. E. · Cancer Res. · 1978 · 38 · 3817
24. 10.1158/0008-5472.CAN-14-029010.1158/0008-5472.CAN-14-0290 ↗
25. 10.1038/nbt.228710.1038/nbt.2287 ↗
26. 10.1038/nrc175010.1038/nrc1750 ↗
27. 10.1089/10430340075003849910.1089/104303400750038499 ↗
28. 10.1038/nrd466310.1038/nrd4663 ↗
29. 10.1038/ng.233010.1038/ng.2330 ↗
30. 10.1097/GIM.0b013e3181d5f73b10.1097/GIM.0b013e3181d5f73b ↗
31. 10.1038/onc.2010.62210.1038/onc.2010.622 ↗
32. 10.1038/onc.2010.34110.1038/onc.2010.341 ↗
33. 10.1038/cgt.2013.2010.1038/cgt.2013.20 ↗
34. 10.1128/JVI.77.8.4646-4657.200310.1128/JVI.77.8.4646-4657.2003 ↗
35. 10.1093/annonc/mdn16710.1093/annonc/mdn167 ↗
36. 10.3892/ijo.2016.352710.3892/ijo.2016.3527 ↗
37. 10.1016/j.jconrel.2010.06.00810.1016/j.jconrel.2010.06.008 ↗
38. 10.1007/s12094-012-0766-610.1007/s12094-012-0766-6 ↗
39. 10.1016/j.biomaterials.2011.03.07110.1016/j.biomaterials.2011.03.071 ↗
40. 10.1038/nm.261710.1038/nm.2617 ↗
41. Gabizon A. · Cancer Res. · 1994 · 54 · 987
42. 10.1021/ma010634610.1021/ma0106346 ↗
43. 10.1128/jvi.70.1.520-532.199610.1128/jvi.70.1.520-532.1996 ↗
44. 10.1056/NEJMra04184210.1056/NEJMra041842 ↗
45. Jaaback K. · Cochrane Database Syst. Rev. · 2016
46. 10.7326/0003-4819-97-6-84510.7326/0003-4819-97-6-845 ↗
47. 10.1016/j.ijpharm.2009.11.01410.1016/j.ijpharm.2009.11.014 ↗
48. 10.1016/j.ygyno.2006.09.02210.1016/j.ygyno.2006.09.022 ↗